3-(2-methylphenyl)succinimide | 69371-19-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 英文名称: 3-(2-methylphenyl)succinimide
• 英文别名: 3-(2-methylphenyl)-pyrrolidine-2,5-dione；3-o-tolyl-pyrrolidine-2,5-dione；3-o-Tolyl-pyrrolidin-2,5-dion；a-Methyl-a-phenyl succinimide；3-(2-methylphenyl)pyrrolidine-2,5-dione
• CAS: 69371-19-3
• 化学式: C₁₁H₁₁NO₂
• 分子量: 189.214
• InChiKey: XYKZYQZDDNDYOM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  46.2
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  聚合甲醛 、 3-(2-methylphenyl)succinimide 、 1-(3-氯苯基)哌嗪 以 乙醇 、 水 为溶剂， 以65%的产率得到N-[{4-(3-chlorophenyl)-piperazin-1-yl}-methyl]-3-(2-methylphenyl)-pyrrolidine-2,5-dione
  参考文献：
  名称：

  Synthesis and anticonvulsant activity of new N-[(4-arylpiperazin-1-yl)-alkyl] derivatives of 3-phenyl-pyrrolidine-2,5-dione

  摘要：

  In the present study, on the development of new anticonvulsants, the series of N-[(4-arylpiperazin-1-yl)-alkyl]-3-(2-methylphenyl)- (8a-e, 10a-h) and 3-(2-trifluoromethyl-phenyl)-pyrrolidine-2,5-diones (9a-e, 11a-i) were synthesized and tested for anticonvulsant activity using the maximal electroshock (MES), subcutaneous pentylenetetrazole (scPTZ) screens. Their neurotoxicity were determined applying the rotorod test. In this series, the most active were N-[(4-phenylpiperazin-1-yl)-methyl]-3-(2-trifluoromethylphenyl)-pyrrolidine-2,5-dione (9a) with the ED50 = 20.78 mg/kg, when given orally to rats and N-[3-(4-(3-trifluoromethylphenyl)-piperazin-1-yl)-propyl]-3-(2-trifluoromethylphenyl)-pyrrolidine-2,5-dione (11i) with the ED50 = 132.13 mg/kg after intraperitoneally injection to mice. (C) 2008 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2008.05.020
• 作为产物：
  描述：

  2-邻甲苯基琥珀酸 在 氨 、 水 作用下， 生成 3-(2-methylphenyl)succinimide
  参考文献：
  名称：

  Anticonvulsants. IV. An Investigation of α-(Substituted phenyl)-succinimides

  摘要：

  DOI：

  10.1021/ja01120a044

文献信息

• Superacidic Activation of Maleimide and Phthalimide and Their Reactions with Cyclohexane and Arenes
  作者：Konstantin Yu. Koltunov、G. K. Surya Prakash、Golam Rasul、George A. Olah

  DOI：10.1002/ejoc.200600486

  日期：2006.11

  When activated in the CF3SO3H/SbF5 acid system maleimide (1) and phthalimide (2) undergo selective ionic hydrogenation with cyclohexane to give 1,5-dihydropyrrol-2-one (3) and phthalimidine (11), respectively. When treated with aluminum halides, N-phenylmaleimide (4) reacts with cyclohexane to give N-phenylsuccinimide (5), whereas 2 still gives 11. Imide 1 also condenses with benzene in trifluoromethanesulfonic

  当在 CF3SO3H/SbF5 酸体系中活化时，马来酰亚胺 (1) 和邻苯二甲酰亚胺 (2) 与环己烷进行选择性离子氢化，分别得到 1,5-二氢吡咯-2-酮 (3) 和邻苯二甲酰亚胺 (11)。当用卤化铝处理时，N-苯基马来酰亚胺 (4) 与环己烷反应生成 N-苯基琥珀酰亚胺 (5)，而 2 仍然生成 11。酰亚胺 1 也在三氟甲磺酸 (CF3SO3H) 中与苯缩合生成 1,5-二氢- 5,5-diphenylpyrrol-2-one (7) 作为主要产品。然而，在卤化铝存在下，1 与苯、甲苯和邻二氯苯反应，分别生成 3-芳基琥珀酰亚胺 8-10。在三氟甲磺酸和卤化铝的作用下，酰亚胺 2 与苯反应生成 3,3-二苯基邻苯二甲酰亚胺 (12)。这些反应的机理，讨论了超亲电双阳离子中间体的潜在参与。(© Wiley-VCH Verlag GmbH & Co. KGaA, 69451 Weinheim
• Agent for medicamentous treatment of acute and chronic pain
  申请人：Lewin Gary

  公开号：US20060110332A1

  公开（公告）日：2006-05-25

  The invention relates to an agent for the medicamentous treatment of acute and chronic pain, in particular of allodynia and hyperalgesia. Fields of application of the invention are medice and the pharmaceutical industry. A new pharmaceutical composition for the treatment of acute and/or chronic pain, in particular allodynia and hyperalgesiais provided, the pharmaceutical composition comprising calcium channel blockers which are suitable for blocking voltage-dependent calcium channels, in particular of the T-type, more preferably the CaV3.2 channel and/or of the L-type. Mibefradil and dihydropyridines can, for instance, be used as calcium channel blockers.

  本发明涉及一种用于治疗急性和慢性疼痛，特别是异动症和痛觉过敏的药物。本发明的应用领域是医疗和制药业。本发明提供了一种用于治疗急性和/或慢性疼痛，特别是痛觉过敏和痛觉减退的新型药物组合物，该药物组合物包含钙通道阻滞剂，该阻滞剂适用于阻滞电压依赖性钙通道，特别是 T 型钙通道，更优选 CaV3.2 通道和/或 L 型钙通道。例如，米贝地尔和二氢吡啶类可用作钙通道阻滞剂。
• AGENT FOR MEDICAMENTOUS TREATMENT OF ACUTE AND CHRONIC PAIN
  申请人：MAX-DELBRÜCK-CENTRUM FÜR MOLEKULARE MEDIZIN

  公开号：EP1549307A2

  公开（公告）日：2005-07-06
• Anti-metastatic ability of mibefradil and gadolinium
  申请人：Petty R. Howard

  公开号：US20060003020A1

  公开（公告）日：2006-01-05

  The present invention relates to methods for inhibiting tumor cell metastasis in cancer comprising administering a composition comprising a T-type calcium channel inhibitor, such as mibefradil.
• Method for selectively binding a substrate to sorbents by way of at least bivalent bonds
  申请人：Gottschall Klaus

  公开号：US20060292569A1

  公开（公告）日：2006-12-28

  A method for the manufacture of at least one sorbent having at least two different groups, which are capable of binding, for the selective binding of a substrate, characterized in that it comprises the steps (i) to (ii): (i) determining at least two groups capable of binding a sorbent from a synthetic or natural first substrate, (ii) respectivly applying at least two different groups capable of binding a second synthetic or natural substrate to one respective carrier, thereby forming at least one sorbent, whereby the groups are the same groups of step (i) or are groups that are complementary thereto, and the second substrate of step (ii) is the same or different from the first substrate according to step (i), and whereby the groups are determined such that the contributions of the Gibbs energies of the individual groups to the non-covalent bond with the second substrate yield a negative value of the Gibbs energy ΔG, such that a binding strengthening occurs that results in an improved separation selectivity with respect to at least one substance to be separated off.